Analysis of cis-PD-L1/CD80 interaction in autoimmune diseases

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K06526
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47030:Pharmaceutical hygiene and biochemistry-related
• Research Institution: The University of Tokyo
• Principal Investigator: Sugiura Daisuke 東京大学, 定量生命科学研究所, 准教授 (80743963)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 免疫補助受容体 / PD-1 / T細胞

Outline of Final Research Achievements

While cancer immunotherapy targeting immune inhibitory co-receptor PD-1 has achieved great clinical success and attracted considerable attention, the development of methods to treat autoimmune diseases by inducing PD-1 function has not progressed. In this study, we focused on the functional restriction mechanism of PD-1 and developed a novel method to potentiate PD-1 function by removing restriction of PD-1. This method successfully alleviated various autoimmune diseases by suppressing autoreactive T cells through induction of PD-1 function.

Free Research Field

免疫学

Academic Significance and Societal Importance of the Research Achievements

近年、自己免疫疾患の治療法は大きく進歩しているものの、治療効果は限定的であり、より効果の高い治療法の研究開発が求められている。本研究で報告したPD-1機能作動性CD80抗体による治療法は、既存の治療法とは作用点が全く異なり、複数のモデルマウスにおいて高い治療効果を示したことから、今後の臨床応用が期待される。